Company profile: Zymeworks
1.1 - Company Overview
Company description
- Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.
Products and services
- Zanidatamab Zovodotin: A HER2-targeted bispecific antibody-drug conjugate combining zanidatamab with a novel auristatin for tumor cell targeting in HER2-expressing tumors
- Zanidatamab: A bispecific antibody engaging two non-overlapping HER2 epitopes to treat HER2-expressing solid tumors, enabling dual-epitope binding for precise receptor targeting
- ZW191: An antibody-drug conjugate targeting folate receptor-α on various tumors, including ovarian and lung cancers, with a topoisomerase-1 inhibitor payload
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zymeworks
Kolltan
HQ: United States
Website
- Description: Provider of novel monoclonal antibody oncology therapeutics targeting receptor tyrosine kinases (RTKs); develops next-generation mAb drugs based on seminal discoveries from Dr. Joseph Schlessinger's Yale Pharmacology lab; founded in 2007 as a private company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kolltan company profile →
Lightpoint Medical
HQ: United Kingdom
Website
- Description: Provider of intraoperative imaging technology for real-time cancer detection during surgery, including Cerenkov Luminescence Imaging (CLI) to reduce recurrence and reoperation; offers SENSEI®, a miniature gamma probe for minimally-invasive and robot-assisted procedures to detect radiation and guide surgeons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lightpoint Medical company profile →
Ratio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ratio Therapeutics company profile →
Kinnate Biopharma
HQ: United States
Website
- Description: Provider of precision oncology therapeutics for genomically-defined cancers, leveraging structure-based drug discovery and translational research. Pipeline includes exarafenib (KIN-2787), a pan-RAF inhibitor for BRAF/NRAS-driven tumors; KIN-3248 targeting FGFR2/3 alterations in intrahepatic cholangiocarcinoma and urothelial carcinoma; KIN-8741, a selective c-MET inhibitor; and a potentially brain-penetrant CDK4 inhibitor for adult solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinnate Biopharma company profile →
Cirrus Bio
HQ: United States
Website
- Description: Provider of solutions for common health issues that impact well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cirrus Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zymeworks
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zymeworks
2.2 - Growth funds investing in similar companies to Zymeworks
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zymeworks
4.2 - Public trading comparable groups for Zymeworks
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →